Table 2.
FDA‐Approved Long‐Acting Opioid Medications With FDA‐Approved Abuse‐Deterrent Labeling53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
| Brand Name | Active Ingredient | Generic Namea | Technology | Abuse Deterrence Mechanism | Year Approved |
|---|---|---|---|---|---|
| OxyContin® (reformulated) | Oxycodone hydrochloride | Oxycodone OP | INTAC |
Crush‐/extraction‐resistant tablets Oxycodone hydrochloride is dispersed within a PEO polymer matrix |
2010 |
| Embeda® | Morphine sulfate and naltrexone hydrochloride | Morphine‐naltrexone | Sequestered naltrexone | Capsules contain ER morphine pellets, each with a sequestered naltrexone core | 2010 |
| Targiniq™ ER | Oxycodone hydrochloride and naloxone hydrochloride | Oxycodone‐naloxone ER | Naloxone | Tablets contain oxycodone combined with naloxone | 2014 |
| Hysingla® ER | Hydrocodone bitartrate | Hydrocodone ER | RESISTEC |
Crush‐/extraction‐resistant tablets Hydrocodone bitartrate is dispersed within a PEO polymer matrix |
2015 |
| MorphaBond™ ER | Morphine sulfate | Morphine‐ARER | SentryBond | Crush‐/extraction‐resistant tablets | 2015 |
| Xtampza® ER | Oxycodone | Oxycodone DETERx® | DETERx | Capsules contain waxy microspheres of oxycodone base combined with inactive ingredients to form a lipophilic salt | 2016 |
| Arymo® ER | Morphine sulfate | Morphine‐ADER‐IMT | Guardian |
Crush‐/extraction‐resistant tablets PEO matrix and injection molding process |
2017 |
Because some ADF opioids contain the same active ingredient (eg, morphine and oxycodone), each product has been assigned a unique generic name for use in this article.
ADER‐IMT, abuse‐deterrent, extended‐release, injection‐molded tablets; ADF, abuse‐deterrent formulation; ARER, abuse‐resistant, extended‐release; ER, extended release; FDA, U.S. Food and Drug Administration; PEO, polyethylene oxide.